Research Journal of Medical Sciences
ISSN: Online 1993-6095ISSN: Print 1815-9346
Abstract
Daratumumab is a monoclonal IgG1K antibody that targets CD38, which is overexpressed in myeloma cells. It works by causing complement-mediated cytotoxicity, antibody-dependent cell cytotoxicity and apoptosis. We enrolled 20 patients in our study: 7 newly diagnosed (NDMM) and 13 relapsed refractory patients. The patients were 58 years old on average. Daratumumab was given to six NDMM patients in conjunction with bortezomib, cyclophosphamide and dexamethasone (VCD) and one patient in combination with VR (lenalidomide) D. The 13 patients with relapsed refractory (RRMM) illness had previously had a median of three prior regimens, including proteasome inhibitors (PI) and immunomodulatory medicines (ImiD). All of the newly diagnosed (NDMM) patients displayed high-risk features. After four cycles, the overall response rate (ORR) for NDMM patients was 71% and 76% for RRMM patients. Stringent complete response (sCR) was attained by 28.5% (2/7) of NDMM patients and 7% (1/13) of RRMM patients. Unfortunately, five individuals died as a result of many comorbidities and advanced illness stage. Daratumumab-based regimens were well tolerated, with no reports of grade 3/4 adverse events.
How to cite this article:
Damodar Das, Jina Bhattacharyya and Sonal Paul. Daratumumab in Multiple Myeloma Patients: A Real World Single Center Experience.
DOI: https://doi.org/10.36478/10.59218/makrjms.2023.8.42.46
URL: https://www.makhillpublications.co/view-article/1815-9346/10.59218/makrjms.2023.8.42.46